ABSTRACT
Lung interstitial diseases and bullae are described as possible complications of neurofibromatosis type-1 (NF-1), a genetic disorder inherited as a autosomal-dominant trait. We report the case of a 16-year-old male non-smoker with NF-1, who presented with pneumothorax caused by ruptured lung bullae. The case of this young patient, successfully treated by video-assisted thoracoscopic resection of bullae, supports the concept that pulmonary alterations may be part of the NF-1 syndrome, rather than as an unrelated complication.
Subject(s)
Lung Diseases/etiology , Lung/abnormalities , Neurofibromatosis 1/complications , Adolescent , Diagnosis, Differential , Humans , Lung/diagnostic imaging , Lung/surgery , Lung Diseases/diagnosis , Lung Diseases/surgery , Male , Neurofibromatosis 1/diagnosis , Thoracic Surgery, Video-Assisted , Tomography, X-Ray ComputedABSTRACT
The 5-year survival rate of marginally resectable nonsmall cell lung cancer (NSCLC) patients treated by platinum/gemcitabine induction chemotherapy and surgery is not well documented. We studied 47 consecutive patients with NSCLC stage IIIA-IIIb (non-N3) treated with platinum/gemcitabine induction chemotherapy (median: 3 cycles) and evaluated the objective response, resectability, surgical morbidity/mortality and long-term survival rate. The induction chemotherapy was completed by 45/47 patients. Objective response was: 36% partial, 32% stable disease, 28% progression, 0% complete; two patients (4%) died during induction chemotherapy. Tumor resectability was 74%, postoperative morbidity 34%, mortality nil. 26% of patients were unresectable. in the whole cohort the 5-year survival was 25% (95%CI, 17%-32%) and the median survival was 22 months (28 months in resected patients; 7 months in unresectable).In conclusion, in the intention-to-treat population undergoing platinum/gemcitabine induction chemotherapy, resectability was high (74%) and the 5-year survival rate was 25%. Median survival in resected cases was three-fold greater than in the unresected.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/mortality , Lung Neoplasms/mortality , Adolescent , Adult , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/therapy , Cisplatin/administration & dosage , Combined Modality Therapy , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Middle Aged , Neoplasm Staging , Pneumonectomy , Prospective Studies , Remission Induction , Retrospective Studies , Survival Rate , Treatment Outcome , Young Adult , GemcitabineABSTRACT
Practices related to vaccines and transfusions aren't free of risk as regards complications and undesired effects. The no. 210/92 law lays down payments to people who are damaged in consequence of the administration of obligatory vaccines, transfusions and haemoderivatives. Our study valued law's sticking, analysing applications for payment sent in by damaged people to some ASL of Lazio and Abruzzo, in the period 1992-2000.
